logo

Trovagene Inc. (TROV)



Trade TROV now with
  Date
  Headline
5/23/2019 8:13:39 AM Trovagene And Nektar Enter Research Collaboration To Explore Combination Of Onvansertib And ONZEALD
5/7/2019 4:21:59 PM Trovagene Q1 Loss/share $1.02 Vs. Loss $6.23 Year Ago
4/23/2019 8:09:16 AM Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax
4/5/2019 8:19:25 AM Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented
4/2/2019 8:06:21 AM Trovagene Presents Early Data From Ongoing Phase 2 Study Evaluating Onvansertib In Combination With Zytiga
3/13/2019 8:31:17 AM Trovagene Receives $3.0 Mln From Exercise Of Warrants
3/12/2019 8:32:36 AM Trovagene Regains Compliance With Nasdaq Listing Requirements
3/6/2019 4:29:32 PM Trovagene Q4 Loss/share $1.09 Vs. Loss $4.61 Year Ago
2/28/2019 8:42:03 AM Trovagene To Present Data From Clinical Programs Of Onvansertib In AML And MCRPC
1/23/2019 8:33:18 AM Trovagene Announces New Patent Issued For Combination Of Onvansertib With Anti-Androgen Drugs
10/3/2018 8:36:06 AM Trovagene In Deal With MIT For Combination Therapy Of Anti-Androgens, Polo-like Kinase Inhibitors In Prostate Cancer
9/27/2018 8:36:44 AM Trovagene Completes Dosing Cohort Of Patients Treated With Onvansertib With Decitabine In Ongoing Phase 1b/2 AML Trial
8/29/2018 8:32:01 AM Trovagene Announces EC Grants Orphan Drug Designation To Onvansertib For Acute Myeloid Leukemia In Europe
8/16/2018 8:04:22 AM Trovagene Completes Second Dosing Cohort Of Onvansertib In Ongoing Phase 1b/2 AML Trial
8/15/2018 8:09:35 AM Trovagene Receives USAN Approval For "Onvansertib" As Nonproprietary Name For PCM-075